-
Original Article
-
J Korean Soc Coloproctol. 2001;17(3):135-140.
- Increase of Plasma TGF-beta1 Level in Colorectal Cancer Patients.
-
Lim, Chang Ki , Choi, In Young , Shin, Hoon , Ryu, Min Hee , Sohn, Seung Kook , Jin, Seung Won
-
1Central Research Institute, Hanmi Pharmaceutical Co., Ltd., Korea. swjin@hanmi.co.kr
2Department of Internal Medicine, College of Medicine, Seoul National University, Korea..
3Department of Surgery, College of Medicine, Yonsei University, Seoul, Korea.
- Abstract
- PURPOSE: Many kinds of malignant tissues, including colorectal cancer were reported to overexpress transforming growth factor-beta1 (TGF-beta1) gene. However, little work has been done on the circulating TGF-beta1 and the association of TGF-beta1 with progression in patients with malignant tumors. In this study, we measured the plasma level of TGF-beta1 in colorectal cancer patients.
METHODS
Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma TGF-beta1 level in 52 colorectal cancer patients and 290 normal controls. And carcinoembryonic antigen (CEA) as a tumor marker was compared with TGF-beta1 in the aspects of sensitivity and specificity.
RESULTS
The mean plasma TGF-beta1 levels were 1.219 +/- 0.834 (0.272~5.772) ng/mL in normal control and 8.207 +/- 2.428 (1.392~39.241) ng/mL in colorectal cancer. In comparison with CEA, TGF-beta1 is more potent in cancer diagnostic sensitivity.
CONCLUSIONS
The results of this study suggest that the plasma TGF-beta1 level can be a useful tumor marker in colorectal cancer patients.
Keywords :CEA;Colorectal cancer;ELISA;TGF-beta1;Tumor marker
